A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Eliquis

  • FDA Approval for Apixaban (Eliquis) for A. Fib.

    Stephan Moll, MD writes… Today (Dec 28th, 2012) the FDA approved apixaban for the prevention of  stroke and systemic arterial thromboembolism in patients with atrial fibrillation, based on the ARISTOTLE study [ref 1].  The FDA press release is here.

  • Apixaban (Eliquis) News – Plus Update On The Big Four New Oral Anticoagulants

    There is a lot of appropriate interest and excitement today about one of the four new oral anticoagulants in development – Apixaban (Eliquis). Data from the large ARISTOTLE trial were published today in the NEJM, showing that in patients with atrial fibrillation Apixaban was more effective in preventing stroke and systemic thromboembolism, caused less major bleeding, and resulted…

  • Apixaban (Eliquis): Good News

    Eliquis (Apixaban) is one of the 4 promising new oral anticoagulants that (a) do not require routine monitoring of its anticoagulant effect and (b) work independently of the vitamin K pathway.